Multiple Myeloma - A New Era of Treatment Strategies.

By:

Podar, Klaus

Contributor(s):

Anderson, Kenneth C

Material type: Text

TextPublication details: Sharjah : Bentham Science Publishers, 2012.Description: 1 online resource (217 pages)Content type:

text

Media type:

computer

Carrier type:

online resource

ISBN:

9781608052974
1608052974

Subject(s):

Genre/Form:

Additional physical formats: Print version:: Multiple Myeloma - A New Era of Treatment Strategies.DDC classification:

616.99/418 616.99418

LOC classification:

RC280.B6

Online resources:

Click here to access online

Contents:

01 Multiple Myeloma -- A New Era of Treatment Strategies.pdf; 02 Cover Page; 03 REVISED eBooks End User License Agreement-Website; 04 TABLE OF CONTENTS; 05 Foreword; 06 PREFACE; 07 Contributors; 08 Section 1; 09 Chapter 01; 10 Chapter 02; 11 Chapter 03; 12 Section 2; 13 Chapter 04; 14 Chapter 05; 15 Chapter 06; 16 Chapter 07; 17 Chapter 08; 18 Section 3; 19 Chapter 9; 20 Chapter 10; 21 Chapter 11; 22 Section 4; 23 Chapter 12; 24 Chapter 13; 25 INDEX.

Summary: Multiple Myeloma (MM), the second most common blood cancer in adults, is a clonal plasma cell malignancy within the bone marrow characterized by osteolytic bone lesions, renal disease, and immunodeficiency. It is now well established that MM cell- induced disruption of the bone marrow homeostasis between the highly organized cellular and extracellular compartments supports MM cell proliferation, survival, migration, and drug resistance via activation of various signaling pathways. Based on this knowledge, the prototypic drugs thalidomide, bortezomib, and lenalidomide, which target both MM cell.

Item type:

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

Holdings
Item type	Home library	Collection	Call number	Materials specified	Status	Date due	Barcode
Electronic-Books	OPJGU Sonepat- Campus	E-Books EBSCO			Available

Multiple Myeloma (MM), the second most common blood cancer in adults, is a clonal plasma cell malignancy within the bone marrow characterized by osteolytic bone lesions, renal disease, and immunodeficiency. It is now well established that MM cell- induced disruption of the bone marrow homeostasis between the highly organized cellular and extracellular compartments supports MM cell proliferation, survival, migration, and drug resistance via activation of various signaling pathways. Based on this knowledge, the prototypic drugs thalidomide, bortezomib, and lenalidomide, which target both MM cell.

Print version record.

eBooks on EBSCOhost EBSCO eBook Subscription Academic Collection - Worldwide

There are no comments on this title.

to post a comment.